Overview
Sandoz Group AG, based in Switzerland, is a global leader in the pharmaceutical sector, particularly recognized for its specialization in generic and biosimilar medicines. As a division of Novartis, one of the world's foremost pharmaceutical companies, Sandoz is fundamental in making accessible, high-quality medicines available, aiming to address some of the most urgent medical needs and ensuring cost-effective patient care. Key projects include pioneering work in biosimilars, with significant advancements in oncology and autoimmune disease treatments, alongside a robust pipeline designed to enhance global healthcare solutions. Sandoz maintains a firm commitment to innovation, safety, and sustainability, constantly seeking to expand its impact through strategic growth and development in the pharmaceutical industry.
Basic Stats
The share price of Sandoz Group AG as of 4 September 2025 is CHF 49,14 / share. This is a decrease of -2.03% from the prior week. The market cap (or net worth) of Sandoz Group AG as of 5 September 2025 is CHF 21.228,48 MM.
The Factor Analysis chart (below right) shows a view of Sandoz Group AG from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 21,228.48 MM |
| EV | |
| Shares Out. | 432.00 MM |
| Earnings Date | |
| EPS (TTM) | 0.53 |
| Dividend Yield | 1.22 % |
| Ex-Dividend Date | 2025-04-17 |
| Borrow Rate | 0.73 |
| Short Shares Avail. | 10.00 MM |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | 38.03 % |
| Volatility (1 yr) | 0.30 |
| Beta | 1.11 |
| Sharpe Ratio (1 yr) | 1.14 |
| Sortino Ratio (1 yr) | 1.89 |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | 0.01 |
| ROE | 0.03 |
| ROIC | 0.02 |
| CROIC | 0.05 |
| OCROIC | 0.07 |
| Implied Volatility | |
| Put/Call OI Ratio |
| Growth | 41.15 /100 |
| Profitability | 55.93 /100 |
| Quality Score | 48.79 /100 |
| Value Score | |
| Momentum Score | 71.03 /100 |
| Stability (Low Vol) Score | 73.22 /100 |
| Analyst Sentiment | 46.66 /100 |
| Fund Sentiment | 72.44 /100 |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | 22.94 /100 |
| QVM Score | |
| Piotroski F-SCORE | 6.00 /9 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Sandoz Group AG is CHF 47,88. The forecasts range from a low of CHF 34,34 to a high of CHF 59,85. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Sandoz Group AG. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2023-12-08 | BERENBERG | Buy | Buy | Maintains |
| 2023-12-05 | REDBURN ATLANTIC | Buy | Buy | Maintains |
| 2024-08-07 | BNP PARIBAS EXANE | Outperform | Outperform | Maintains |
| 2024-08-04 | REDBURN ATLANTIC | Buy | Buy | Maintains |
| 2024-07-16 | BNP PARIBAS EXANE | Outperform | Outperform | Maintains |
| 2024-07-07 | BERENBERG | Buy | Buy | Maintains |
| 2024-06-19 | BNP PARIBAS EXANE | Outperform | Outperform | Maintains |
| 2024-05-06 | STIFEL EUROPE | Buy | Buy | Maintains |
| 2024-03-13 | SOCIETE GENERALE | Buy | Buy | Maintains |
| 2023-12-07 | BERENBERG | Buy | Buy | Maintains |
| 2023-12-04 | REDBURN ATLANTIC | Buy | Buy | Maintains |
| 2024-11-05 | REDBURN ATLANTIC | Buy | Buy | Maintains |
| 2024-10-31 | BERENBERG | Buy | Hold | Downgrade |
| 2024-10-30 | STIFEL EUROPE | Buy | Buy | Maintains |
| 2024-08-21 | BNP PARIBAS EXANE | Outperform | Outperform | Maintains |
| 2024-08-12 | BERENBERG | Buy | Buy | Maintains |
| 2025-03-31 | BERENBERG | Hold | Hold | Maintains |
| 2025-03-21 | REDBURN ATLANTIC | Buy | Buy | Maintains |
| 2025-03-05 | JEFFERIES | Buy | Buy | Maintains |
| 2025-03-05 | STIFEL EUROPE | Buy | Buy | Maintains |
| 2025-07-16 | ROTHSCHILD & CO REDBURN | Buy | Buy | Maintains |
| 2025-06-30 | BERENBERG | Hold | Hold | Maintains |
| 2025-06-05 | JEFFERIES | Buy | Buy | Maintains |
